Home › Funds › Andera Partners › MLYS
Andera Partners position in MLYS
Mineralys Therapeutics, Inc. · Health Care
Andera Partners reported holding 1,591,917 shares of MLYS (Mineralys Therapeutics, Inc.) in its Q3 2026 13F filing — a position valued at US$40.0M, representing 22.77% of its reported portfolio and ranking #2 among its reported holdings. Andera Partners has disclosed MLYS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-10-17 · Source: SEC EDGAR Form 13F-HR
How Andera Partners's MLYS position evolved
Andera Partners first disclosed a stake in MLYS in Q4 2025 at 1,591,917 shares (US$57.8M). Across 4 filings, Andera Partners held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,591,917 shares valued at US$40.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.59M | $57.77M | New |
| Q1 2026 | 1.59M | $43.13M | Hold |
| Q2 2026 | 1.59M | $42.95M | Hold |
| Q3 2026 | 1.59M | $40.00M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLYS and 13F data
MLYS (Mineralys Therapeutics, Inc.) is a Health Care company. 53 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLYS
- RA CAPITAL MANAGEMENT, L.P. 7.69M sh · $207.55M · Q2 2026
- Catalys Pacific, LLC 7.80M sh · $196.00M · Q3 2026
- Samsara BioCapital, LLC 5.87M sh · $158.40M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.96M sh · $106.79M · Q2 2026
- Laurion Capital Management LP 2.51M sh · $67.62M · Q2 2026
- ORBIMED ADVISORS LLC 2.11M sh · $56.94M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 1.56M sh · $42.20M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.47M sh · $39.66M · Q2 2026
- Ghisallo Capital Management LLC 1.12M sh · $30.35M · Q2 2026
- Logos Global Management LP 1.05M sh · $28.33M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.04M sh · $28.06M · Q2 2026
- Davern Capital Partners, LP 858.75K sh · $23.17M · Q2 2026
More on Andera Partners
FAQ
How long has Andera Partners held MLYS?
Andera Partners has disclosed MLYS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Andera Partners's current position in MLYS?
As of Q3 2026, Andera Partners holds 1.59M shares of MLYS (Mineralys Therapeutics, Inc.), valued at $40.00M, representing 22.77% of its reported portfolio and ranking #2.
Has Andera Partners been buying or selling MLYS?
In the latest 13F filing (Q3 2026), Andera Partners held unchanged its position in MLYS.
Which other funds hold MLYS?
Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Catalys Pacific, LLC, Samsara BioCapital, LLC, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.